Developer docs
API playgroundTry for free, no card

Search company profiles

Rappta Therapeutics

Full company profile

uuid0002zsb

Namestring
Rappta Therapeutics
Legal namestring
Rappta Therapeutics Oy
Company typeenum
Private
Founded yearint
2020
Descriptiontext

Rappta Therapeutics Oy is a late preclinical-stage biopharmaceutical company headquartered in Helsinki, Finland, with team operations spanning Finland and the United States. The company is developing first-in-class molecular glue small molecules that reactivate Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme whose inactivation is implicated in multiple cancers including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers. Rappta's compounds act as molecular glues that enable the three subunits of PP2A (scaffolding A, catalytic C, and regulatory B) to bind together correctly, reforming the active enzyme complex to negatively regulate oncogenic signaling pathways. The platform is anchored by proprietary high-resolution PP2A-Drug complex structural data and a tool set developed by founding scientists who are pre-eminent PP2A researchers with seminal publications in Cell, J Clin Invest, Sci Transl Med, and Cancer Res.

The company's lead asset, RPT04402, was out-licensed globally to SpringWorks Therapeutics in January 2025 under a deal in which SpringWorks paid $13M upfront and assumed responsibility for global development and commercialization, including filing an IND application by end of 2025. Rappta retains eligibility for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales. The company generates revenue exclusively through licensing agreements and has no commercialized products. The underlying PP2A reactivation platform has stated potential to address a broader range of human diseases beyond oncology, given PP2A's central role in protein phosphorylation regulation.

Rappta was founded in 2020 and has raised approximately $10.6M in equity financing from Advent Life Sciences, Novartis Venture Fund, and Novo Holdings. Its go-to-market model is partnership-driven: Rappta develops and out-licenses proprietary molecular glue compounds, while larger pharmaceutical partners fund late-stage development and commercialization. The company's scientific credibility rests on the deep domain expertise of its founding team and the proprietary structural and biological understanding of the PP2A target, which has historically been considered very difficult to drug pharmacologically.

Short descriptiontext

Rappta Therapeutics is a late preclinical-stage biopharmaceutical company developing first-in-class molecular glue small molecules that reactivate the PP2A tumor suppressor for cancer treatment, with lead asset RPT04402 out-licensed globally to SpringWorks Therapeutics in January 2025.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHelsinki, Finland
HQ citystring
Helsinki
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
molecular glue therapeutics, PP2A reactivation, oncology drug discovery, tumor suppressor activators, cancer small molecules
Industry2 codes
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Rappta generates revenue through licensing agreements with pharmaceutical partners. Under the SpringWorks partnership, Rappta received $13 million upfront and is eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales.

arcticstartup.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Rappta Therapeutics develops a proprietary molecular glue-based technology platform that reactivates Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme. Its lead product candidate, RPT04402, is a first-in-class molecular glue designed to enable the three PP2A subunits to bind together, reforming the active PP2A complex to target oncogenic substrates in cancer. The company primarily monetizes this through licensing deals with larger pharmaceutical partners who handle downstream development and commercialization.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • IND filing targeted by end of 2025 for RPT04402
+1 more record
Product overview1 text field

Rappta Therapeutics is a late preclinical stage biopharmaceutical company developing a proprietary molecular glue technology platform centered on PP2A (Protein Phosphatase 2A) reactivation. The core product, RPT04402, is a first-in-class molecular glue therapeutic candidate for cancer treatment. The PP2A Reactivation Technology Platform enables the development of anti-cancer molecules that restore PP2A enzyme activity by facilitating subunit binding, addressing a historically difficult-to-target tumor suppressor. The company has leveraged high-resolution PP2A-drug complex structures to develop an entire series of compounds with potential for treating a broad range of human diseases beyond cancer.

Product and service2 records
1RPT04402
CategoryOncology Therapeutic Candidate
Description

RPT04402 is Rappta's lead first-in-class molecular glue therapeutic candidate targeting Protein Phosphatase 2A (PP2A) for cancer treatment. It acts as a small-molecule glue that allows the three subunits of PP2A (scaffolding A, catalytic C, regulatory B) to bind together, driving PP2A complex reformation to target oncogenic substrates. The candidate is being advanced through a global license partnership with SpringWorks Therapeutics, intended for oncology indications including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers.

2PP2A Reactivation Technology Platform
CategoryDrug Discovery Technology Platform
Description

Rappta's proprietary molecular glue-based technology platform that enables therapeutic reactivation of PP2A, a key tumor suppressor enzyme regulating protein de-phosphorylation and tumor growth. The platform leverages proprietary tools, deep understanding of PP2A biology, and high-resolution PP2A-drug complex structural data to develop an entire series of compounds that interlock PP2A subunits and specifically reactivate PP2A's tumor suppressive function. The platform has potential applications across a broad range of human diseases beyond oncology due to PP2A's central role in protein phosphorylation regulation.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-13
Description

Global license agreement for RPT04402, a first-in-class molecular glue targeting the PP2A enzyme for cancer treatment. SpringWorks paid $13 million upfront and will oversee global development and commercialization, including filing an IND application by end of 2025. Rappta remains eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties. The partnership leverages Rappta's proprietary structural data to advance PP2A reactivation as a therapeutic approach.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pioneer in targeted protein degradation and molecular glue degraders for oncology. Highly comparable as a fellow molecular-glue-based oncology platform developing first-in-class small molecules, though Arvinas focuses on induced degradation rather than Rappta's PP2A reactivation.

TypeDirect peer
Description

Clinical-stage biotech developing molecular glue degraders for cancer and other diseases. Directly comparable as a molecular-glue platform targeting previously undruggable proteins in oncology, with similar preclinical-to-early-clinical stage assets.

TypeDirect peer
Description

Developer of targeted protein degradation therapeutics, including molecular glues, for cancer and other diseases. Comparable as a small-molecule degrader/glue platform focused on oncology, pursuing similar first-in-class opportunities against historically challenging targets.

TypeDirect peer
Description

Clinical-stage biotech focused on targeted protein degradation using heterobifunctional small molecules and molecular glues. Comparable as a fellow modality-platform company developing oncology therapeutics against hard-to-drug targets.

TypeBroad incumbent
Description

Rappta's global development and commercialization partner for RPT04402. Comparable as a clinical/commercial-stage oncology company with broader pipeline scope, providing development infrastructure and downstream value capture through milestones and royalties.

TypeEmerging player
Description

Clinical-stage oncology company developing medicines targeting chromatin biology. Comparable as a platform-based, target-novel small-molecule oncology company using proprietary structural/biological insights to drug previously undruggable targets.

TypeEmerging player
Description

Precision oncology company developing synthetic lethality-based therapeutics. Comparable as a small-molecule oncology platform addressing defined genomic-defined patient populations with novel mechanism-of-action drugs.

TypeEmerging player
Description

Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a structure-guided oncology platform targeting historically difficult oncogenic drivers with a similar discovery-to-development model.

TypeOthers
Description

Computational drug discovery platform company combining physics-based simulation with structure-guided small-molecule design. Comparable as a structure-based drug design platform where high-resolution structural insights drive lead compound development in oncology and other therapeutic areas.

TypeEmerging player
Description

Clinical-stage oncology company developing small-molecule therapies against RNA-modifying proteins. Comparable as an early-stage small-molecule oncology platform pursuing first-in-class mechanism against historically undruggable targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Rappta Therapeutics

Oncology Drug Discoveryrappta-therapeutics.com

Rappta Therapeutics is a late preclinical-stage biopharmaceutical company developing first-in-class molecular glue small molecules that reactivate the PP2A tumor suppressor for cancer treatment, with lead asset RPT04402 out-licensed globally to SpringWorks Therapeutics in January 2025.

What Rappta Therapeutics does

Rappta Therapeutics Oy is a late preclinical-stage biopharmaceutical company headquartered in Helsinki, Finland, with team operations spanning Finland and the United States. The company is developing first-in-class molecular glue small molecules that reactivate Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme whose inactivation is implicated in multiple cancers including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers. Rappta's compounds act as molecular glues that enable the three subunits of PP2A (scaffolding A, catalytic C, and regulatory B) to bind together correctly, reforming the active enzyme complex to negatively regulate oncogenic signaling pathways. The platform is anchored by proprietary high-resolution PP2A-Drug complex structural data and a tool set developed by founding scientists who are pre-eminent PP2A researchers with seminal publications in Cell, J Clin Invest, Sci Transl Med, and Cancer Res.

The company's lead asset, RPT04402, was out-licensed globally to SpringWorks Therapeutics in January 2025 under a deal in which SpringWorks paid $13M upfront and assumed responsibility for global development and commercialization, including filing an IND application by end of 2025. Rappta retains eligibility for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales. The company generates revenue exclusively through licensing agreements and has no commercialized products. The underlying PP2A reactivation platform has stated potential to address a broader range of human diseases beyond oncology, given PP2A's central role in protein phosphorylation regulation.

Rappta was founded in 2020 and has raised approximately $10.6M in equity financing from Advent Life Sciences, Novartis Venture Fund, and Novo Holdings. Its go-to-market model is partnership-driven: Rappta develops and out-licenses proprietary molecular glue compounds, while larger pharmaceutical partners fund late-stage development and commercialization. The company's scientific credibility rests on the deep domain expertise of its founding team and the proprietary structural and biological understanding of the PP2A target, which has historically been considered very difficult to drug pharmacologically.

Rappta Therapeutics firmographics

Firmographics
Name
Rappta Therapeutics
Legal name
Rappta Therapeutics Oy
Website
https://rappta-therapeutics.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
Rappta Therapeutics is a late preclinical-stage biopharmaceutical company developing first-in-class molecular glue small molecules that reactivate the PP2A tumor suppressor for cancer treatment, with lead asset RPT04402 out-licensed globally to SpringWorks Therapeutics in January 2025.
Ownership category
akta.pro rank

Rappta Therapeutics industry classification

Industry
Product category
Oncology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Molecular glue therapeutics
  • PP2A reactivation
  • Oncology drug discovery
  • Tumor suppressor activators
  • Cancer small molecules

Where Rappta Therapeutics is headquartered

Location

Headquarters

HQ city
Helsinki
HQ country
Finland
HQ region
Europe

Offices1 record

Markets served

Rappta Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Rappta generates revenue through licensing agreements with pharmaceutical partners. Under the SpringWorks partnership, Rappta received $13 million upfront and is eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties on net sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Rappta Therapeutics product offering

Product offering

Core offering

Rappta Therapeutics develops a proprietary molecular glue-based technology platform that reactivates Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme. Its lead product candidate, RPT04402, is a first-in-class molecular glue designed to enable the three PP2A subunits to bind together, reforming the active PP2A complex to target oncogenic substrates in cancer. The company primarily monetizes this through licensing deals with larger pharmaceutical partners who handle downstream development and commercialization.

Product overview

Rappta Therapeutics is a late preclinical stage biopharmaceutical company developing a proprietary molecular glue technology platform centered on PP2A (Protein Phosphatase 2A) reactivation. The core product, RPT04402, is a first-in-class molecular glue therapeutic candidate for cancer treatment. The PP2A Reactivation Technology Platform enables the development of anti-cancer molecules that restore PP2A enzyme activity by facilitating subunit binding, addressing a historically difficult-to-target tumor suppressor. The company has leveraged high-resolution PP2A-drug complex structures to develop an entire series of compounds with potential for treating a broad range of human diseases beyond cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • RPT04402 RPT04402 is Rappta's lead first-in-class molecular glue therapeutic candidate targeting Protein Phosphatase 2A (PP2A) for cancer treatment. It acts as a small-molecule glue that allows the three subunits of PP2A (scaffolding A, catalytic C, regulatory B) to bind together, driving PP2A complex reformation to target oncogenic substrates. The candidate is being advanced through a global license partnership with SpringWorks Therapeutics, intended for oncology indications including KRAS-driven tumors, MEK inhibitor-resistant cancers, castration-resistant prostate cancer, and MYC-driven cancers.
  • PP2A Reactivation Technology Platform Rappta's proprietary molecular glue-based technology platform that enables therapeutic reactivation of PP2A, a key tumor suppressor enzyme regulating protein de-phosphorylation and tumor growth. The platform leverages proprietary tools, deep understanding of PP2A biology, and high-resolution PP2A-drug complex structural data to develop an entire series of compounds that interlock PP2A subunits and specifically reactivate PP2A's tumor suppressive function. The platform has potential applications across a broad range of human diseases beyond oncology due to PP2A's central role in protein phosphorylation regulation.

Quantifiable outcome

  • IND filing targeted by end of 2025 for RPT04402
  • +1 more outcomes

Companies that use Rappta Therapeutics

Customer profile

Segments1 record

Ideal customer profiles1 record

Rappta Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Rappta Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SpringWorks TherapeuticscoreStrategic or Co-development Partner · 13 January 2025Global license agreement for RPT04402, a first-in-class molecular glue targeting the PP2A enzyme for cancer treatment. SpringWorks paid $13 million upfront and will oversee global development and commercialization, including filing an IND application by end of 2025. Rappta remains eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties. The partnership leverages Rappta's proprietary structural data to advance PP2A reactivation as a therapeutic approach.

Scale indicators3 records

Recent moves4 records

Expansion highlights5 records

Rappta Therapeutics competitors and assessment

Company assessment

Direct peers

  • Arvinas: Pioneer in targeted protein degradation and molecular glue degraders for oncology. Highly comparable as a fellow molecular-glue-based oncology platform developing first-in-class small molecules, though Arvinas focuses on induced degradation rather than Rappta's PP2A reactivation.
  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders for cancer and other diseases. Directly comparable as a molecular-glue platform targeting previously undruggable proteins in oncology, with similar preclinical-to-early-clinical stage assets.
  • C4 Therapeutics: Developer of targeted protein degradation therapeutics, including molecular glues, for cancer and other diseases. Comparable as a small-molecule degrader/glue platform focused on oncology, pursuing similar first-in-class opportunities against historically challenging targets.
  • Kymera Therapeutics: Clinical-stage biotech focused on targeted protein degradation using heterobifunctional small molecules and molecular glues. Comparable as a fellow modality-platform company developing oncology therapeutics against hard-to-drug targets.

Broad incumbents

  • SpringWorks Therapeutics: Rappta's global development and commercialization partner for RPT04402. Comparable as a clinical/commercial-stage oncology company with broader pipeline scope, providing development infrastructure and downstream value capture through milestones and royalties.

Emerging players

  • Foghorn Therapeutics: Clinical-stage oncology company developing medicines targeting chromatin biology. Comparable as a platform-based, target-novel small-molecule oncology company using proprietary structural/biological insights to drug previously undruggable targets.
  • Repare Therapeutics: Precision oncology company developing synthetic lethality-based therapeutics. Comparable as a small-molecule oncology platform addressing defined genomic-defined patient populations with novel mechanism-of-action drugs.
  • Black Diamond Therapeutics: Precision oncology company developing allosteric mutation-targeted therapies. Comparable as a structure-guided oncology platform targeting historically difficult oncogenic drivers with a similar discovery-to-development model.
  • Accent Therapeutics: Clinical-stage oncology company developing small-molecule therapies against RNA-modifying proteins. Comparable as an early-stage small-molecule oncology platform pursuing first-in-class mechanism against historically undruggable targets.

Others

  • Schrödinger: Computational drug discovery platform company combining physics-based simulation with structure-guided small-molecule design. Comparable as a structure-based drug design platform where high-resolution structural insights drive lead compound development in oncology and other therapeutic areas.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Rappta Therapeutics social profiles

Digital presence

Rappta Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Rappta Therapeutics leadership team

Management profile

Number of profiles

Profiles4 records

Rappta Therapeutics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Rappta Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Rappta Therapeutics

What does Rappta Therapeutics do?

Rappta Therapeutics develops a proprietary molecular glue-based technology platform that reactivates Protein Phosphatase 2A (PP2A), a key tumor suppressor enzyme. Its lead product candidate, RPT04402, is a first-in-class molecular glue designed to enable the three PP2A subunits to bind together, reforming the active PP2A complex to target oncogenic substrates in cancer. The company primarily monetizes this through licensing deals with larger pharmaceutical partners who handle downstream development and commercialization.

Is Rappta Therapeutics a public or private company?

Rappta Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Rappta Therapeutics founded?

Rappta Therapeutics was founded in 2020. It employs 1 to 10 people.

Where is Rappta Therapeutics based?

Rappta Therapeutics is headquartered in Helsinki, Finland, in the Europe region.

How does Rappta Therapeutics make money?

One revenue line is on record: licensing and Milestone Payments.

Who are Rappta Therapeutics's main competitors?

Direct peers on record are Arvinas, Monte Rosa Therapeutics, C4 Therapeutics and Kymera Therapeutics. SpringWorks Therapeutics is listed as a broad incumbent. Emerging players are Foghorn Therapeutics, Repare Therapeutics, Black Diamond Therapeutics and Accent Therapeutics. Schrödinger is listed as an others.

Does Rappta Therapeutics have an API?

No public API is recorded for Rappta Therapeutics.

What industry is Rappta Therapeutics in?

Rappta Therapeutics's product category is Oncology Drug Discovery. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ArcticstartupFinland’s Rappta Therapeutics partners with SpringWorks for development of novel cancer treatmentFinland's Rappta Therapeutics has entered into a global license agreement with SpringWorks Therapeutics for RPT04402, a first-in-class molecular glue targeting the PP2A enzyme for cancer treatment, with SpringWorks paying $13 million upfront. SpringWorks will oversee global development and commercialization, including filing an Investigational New Drug application by the end of 2025, while Rappta remains eligible for clinical, regulatory, and commercial milestone payments plus tiered royalties. The partnership aims to advance PP2A reactivation as a therapeutic approach, leveraging Rappta's proprietary structural data to target a historically undruggable tumor suppressor enzyme.PR NewswireRappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive OfficerRappta Therapeutics announced the appointment of Sunjeet Sawhney as Chief Executive Officer, effective immediately, with Co-founder Mikko Mannerkoski transitioning to CFO as previously planned. Sunjeet joins from Ipsen, where he served as Global Head of the Oncology Franchise, bringing over 20 years of industry experience to the role. The company is developing first-in-class anti-cancer drugs reactivating PP2A and is backed by investors including Advent Life Sciences, Novartis Bioventures, and Novo Holdings.UnquoteNovartis, Novo lead €9m series-A for Rappta TherapeuticsNovartis Venture Fund and Novo Holdings co-led a €9m series-A round for Finnish biotech Rappta Therapeutics. The company develops anti-cancer tools targeting PP2A, a tumour suppressor. Board members from Novartis, Novo, and Advent Life Sciences joined, with Beat Steffen as chair.FinSMEsRappta Therapeutics Closes €9M Series A FinancingRappta Therapeutics closed a €9M Series A financing co-led by Novartis Venture Fund and Novo Holdings, with participation from Advent Life Sciences and a family office. The company, based in Finland and the US, develops anti-cancer drugs targeting PP2A, a tumor suppressor enzyme. The round also included funding from Business Finland.PR NewswireNovo Seeds co-leads Rappta Therapeutics Series A Financing for the Development of Phosphatase 2A drugsNovo Seeds, the early stage investment team of Novo Holdings, co-led a EUR 9M Series A financing round for Rappta Therapeutics, a biotech company developing first-in-class anti-cancer drugs targeting protein phosphatase 2A (PP2A). Other investors in the round included Novartis Venture Fund, Advent Life Sciences, and one family office. The funding will enable Rappta to accelerate development of its PP2A-reactivating platform and advance lead compounds toward clinical development.PR NewswireRappta Therapeutics Raises Series A Financing for the Development of Phosphatase 2A drugsRappta Therapeutics, a private biotech company based in Finland and the US developing first-in-class anti-cancer drugs targeting protein phosphatase 2A (PP2A), closed a EUR 9 million Series A financing round co-led by Novartis Venture Fund and Novo Holdings, with participation from Advent Life Sciences and a family office. The funding, which also includes backing from Business Finland, the Finnish innovation funding organization, will enable the company to accelerate its platform development and advance lead compounds toward clinical development. The company has assembled a scientific team led by Professor Goutham Narla from the University of Michigan and will be supported by a Scientific Advisory Board led by Dr. William Hahn from Harvard Medical School and the Dana-Farber Cancer Institute.BioWorldMore cashflow: Rappta Therapeutics, Chord Therapeutics close series A roundsChord Therapeutics and Rappta Therapeutics closed series A rounds on Oct. 13. Chord raised €16 million to repurpose cladribine for rare autoimmune disorders, while Rappta raised €9 million to develop small-molecule PP2A activators for cancer.Nordic 9Rappta Therapeutics secured a €9 million Series A funding round co-led by Novartis Venture Fund and Novo HoldingsRappta Therapeutics, a Helsinki-based biotech, secured a €9 million ($10.5M) Series A funding round co-led by Novartis Venture Fund and Novo Holdings. The company is developing first-in-class anti-cancer drugs that reactivate protein phosphatase 2A, a key enzyme in tumor growth.